The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Quantitative Biomarkers Could Be the Next Step for Precision Oncology
Just Enough Downstream Innovation
Downstream Operations Can Relieve the Pressure of Higher Titers and Cell Densities without Undue Disruption
Snag-Free Combing of the Proteome
With the Right Conditioning Raw Samples May Become More Manageable
Love, Science, and Autoimmune Therapy
NYU Professor Advances Autoimmune Disease Therapeutics
For full access to this article login to GEN Select now.
Taming Difficult to Express Proteins
- In small molecule drug development, it is often said that the low-hanging fruit has already been harvested. Most structures that are chemically accessible, manufacturable, and druggable have already been considered. Somewhat analogously, the leading edge in biologics development are proteins that for one reason or other present development ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.